$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000162828016019568 Filed on September 14, 2016

Income Statement

Concept	2016 Q3	2015 Q3
Revenue	$3.670M	$2.822M
YoY Change	30.05%	47.59%
Cost Of Revenue	$2.520M	$2.270M
YoY Change	11.01%	134.02%
Gross Profit	$1.150M	$550.0K
YoY Change	109.09%	-41.49%
Gross Profit Margin	31.34%	19.49%
Selling, General & Admin	$2.459M	$2.346M
YoY Change	4.82%	-6.01%
% of Gross Profit	213.83%	426.55%
Research & Development	$1.211M	$1.100M
YoY Change	10.09%	-22.7%
% of Gross Profit	105.3%	200.0%
Depreciation & Amortization	$39.00K	$37.00K
YoY Change	5.41%	-33.93%
% of Gross Profit	3.39%	6.73%
Operating Expenses	$6.193M	$5.719M
YoY Change	8.29%	1.38%
Operating Profit	-$2.523M	-$2.897M
YoY Change	-12.91%	-22.31%
Interest Expense		$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$9.000K	-$10.00K
YoY Change	-10.0%	-105.38%
Pretax Income	-$2.532M	-$2.907M
YoY Change	-12.9%	-17.95%
Income Tax	$14.00K	$6.000K
% Of Pretax Income
Net Earnings	-$2.546M	-$2.913M
YoY Change	-12.6%	-17.9%
Net Earnings / Revenue	-69.37%	-103.22%
Basic Earnings Per Share		-$0.33
Diluted Earnings Per Share	-$259.1K	-$0.33
COMMON SHARES
Basic Shares Outstanding	9.835M shares	8.702M shares
Diluted Shares Outstanding		8.702M shares

Balance Sheet

Concept	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.460M	$6.760M
YoY Change	-34.02%	121.64%
Cash & Equivalents	$4.463M	$6.760M
Short-Term Investments
Other Short-Term Assets	$350.0K	$370.0K
YoY Change	-5.41%	-19.57%
Inventory
Prepaid Expenses
Receivables	$1.628M	$1.460M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$6.440M	$8.580M
YoY Change	-24.94%	93.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$590.0K	$450.0K
YoY Change	31.11%	9.49%
Goodwill	$669.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.0K	$150.0K
YoY Change	0.0%	-11.76%
Total Long-Term Assets	$1.409M	$1.270M
YoY Change	10.94%	2.01%
TOTAL ASSETS
Total Short-Term Assets	$6.440M	$8.580M
Total Long-Term Assets	$1.409M	$1.270M
Total Assets	$7.849M	$9.850M
YoY Change	-20.31%	73.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.509M	$1.440M
YoY Change	4.79%	8.43%
Accrued Expenses	$220.0K	$420.0K
YoY Change	-47.62%	7.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.426M	$3.760M
YoY Change	17.71%	11.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$247.0K	$190.0K
YoY Change	30.0%	-89.78%
Total Long-Term Liabilities	$247.0K	$190.0K
YoY Change	30.0%	-89.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.426M	$3.760M
Total Long-Term Liabilities	$247.0K	$190.0K
Total Liabilities	$4.673M	$3.950M
YoY Change	18.3%	-24.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.01M
YoY Change
Common Stock	$69.44M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.252M
YoY Change
Treasury Stock Shares	269.7K shares	269.7K shares
Shareholders Equity	$3.176M	$5.900M
YoY Change
Total Liabilities & Shareholders Equity	$7.849M	$9.850M
YoY Change	-20.31%	73.48%

Cashflow Statement

Concept	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$2.546M	-$2.913M
YoY Change	-12.6%	-17.9%
Depreciation, Depletion And Amortization	$39.00K	$37.00K
YoY Change	5.41%	-33.93%
Cash From Operating Activities	-$2.439M	-$2.543M
YoY Change	-4.09%	-8.85%
INVESTING ACTIVITIES
Capital Expenditures	$17.00K	$29.00K
YoY Change	-41.38%	-12.12%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$17.00K	-$29.00K
YoY Change	-41.38%	-3.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.340M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.334M	-$25.00K
YoY Change	-17436.0%
NET CHANGE
Cash From Operating Activities	-$2.439M	-$2.543M
Cash From Investing Activities	-$17.00K	-$29.00K
Cash From Financing Activities	$4.334M	-$25.00K
Net Change In Cash	$1.878M	-$2.597M
YoY Change	-172.31%	-7.91%
FREE CASH FLOW
Cash From Operating Activities	-$2.439M	-$2.543M
Capital Expenditures	$17.00K	$29.00K
Free Cash Flow	-$2.456M	-$2.572M
YoY Change	-4.51%	-8.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	661000	USD
CY2016Q3	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	474000	USD
CY2015Q3	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	1612000	USD
CY2016Q3	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2049000	USD
CY2014Q4	csbr	Monthly Capital Lease Payment MonthlyCapitalLeasePayment	3000	USD
CY2016Q3	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	3	subsidiary
CY2015Q3	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	485000	USD
CY2016Q3	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	511000	USD
CY2016Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	0	USD
CY2016Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P6Y3M18D
CY2016Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	1793781	shares
CY2016Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y
CY2016Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Shares Exchanged In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExchangedInPeriod	1793781	shares
CY2016Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	2109840000	shares
CY2016Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	2109840	shares
CY2016Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	4.92
CY2013Q4	csbr	Stockholders Equity Reverse Stock Split Conversion Ratio StockholdersEquityReverseStockSplitConversionRatio	0.0833
CY2015Q3	csbr	Translational Oncology Solutions TranslationalOncologySolutions	2337000	USD
CY2016Q3	csbr	Translational Oncology Solutions TranslationalOncologySolutions	3159000	USD
CY2016Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	2000000	USD
CY2016Q3	dei	Amendment Flag AmendmentFlag	false
CY2016Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2016Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2016Q3	dei	Document Period End Date DocumentPeriodEndDate	2016-07-31
CY2016Q3	dei	Document Type DocumentType	10-Q
CY2016Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10967491	shares
CY2016Q3	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q3	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2016Q3	dei	Trading Symbol TradingSymbol	CSBR
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1896000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1509000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1312000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1628000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	271000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	220000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	954000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	999000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	63947000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	69429000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	775000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1129000	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4124347	shares
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4264788	shares
CY2016Q2	us-gaap	Assets Assets	5777000	USD
CY2016Q3	us-gaap	Assets Assets	7849000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	4340000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	6440000	USD
CY2016Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	54000	USD
CY2016Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2016Q3	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	86000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	24000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	16000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	27000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	25000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	8000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	78000	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	18000	USD
CY2016Q3	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.05
CY2016Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	715000	USD
CY2016Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	725000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9357000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6760000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2585000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4500000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4463000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2597000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1878000	USD
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8974531	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11237176	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8704846	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10967491	shares
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3139000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2697000	USD
CY2015Q3	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	24000	USD
CY2016Q3	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	42000	USD
CY2015Q3	us-gaap	Depreciation Depreciation	37000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	39000	USD
CY2015Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37000	USD
CY2016Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	45000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2016Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	73000	USD
CY2016Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	77000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1317000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1534000	USD
CY2016Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	669000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2907000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2532000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	22000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-387000	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	398000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	314000	USD
CY2015Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	43000	USD
CY2016Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-51000	USD
CY2015Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-102000	USD
CY2016Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-442000	USD
CY2015Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2016Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	20000	USD
CY2015Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20000	USD
CY2016Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-94000	USD
CY2015Q3	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13000	USD
CY2016Q3	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2015Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	15000	USD
CY2015Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	53000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	99000	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2016Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	5539000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	4673000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5777000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7849000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5306000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4426000	USD
CY2016Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	782000	USD
CY2016Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	785000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4334000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	USD
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1029000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2546449	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10000	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	925000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2543000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2439000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2913101	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2913000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2546000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	5719000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	6193000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2897000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2523000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	233000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	247000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	USD
CY2016Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	742000	USD
CY2016Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	742000	USD
CY2015Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	18000	USD
CY2016Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	USD
CY2016Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	443000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	349000	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4300000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1572000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1589000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	618000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	590000	USD
CY2015Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2000	USD
CY2015Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2016Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1100000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1211000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62466000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65012000	USD
CY2015Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	2822000	USD
CY2016Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3670000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.01774
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.01250
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0157
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.956
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.878
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.732
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	775000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1129000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.928
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0075
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1774069	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.35
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	18542	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7813	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1568191	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1762327	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.85
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2212757	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2154948	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.58
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.22
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2154948	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.22
CY2016Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2016Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.64
CY2016Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.85
CY2016Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.10
CY2016Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.10
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M15D
CY2016Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	238000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	3176000	USD
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2016Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	165000	USD
CY2016Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	185000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8702237	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9835279	shares

Files In Submission

Name	View Source	Status
0001628280-16-019568-index-headers.html	Edgar Link	pending
0001628280-16-019568-index.html	Edgar Link	pending
0001628280-16-019568.txt	Edgar Link	pending
0001628280-16-019568-xbrl.zip	Edgar Link	pending
csbr-20160131.xml	Edgar Link	completed
csbr-20160131.xsd	Edgar Link	pending
csbr-20160131_cal.xml	Edgar Link	unprocessable
csbr-20160131_def.xml	Edgar Link	unprocessable
csbr-20160131_lab.xml	Edgar Link	unprocessable
csbr-20160131_pre.xml	Edgar Link	unprocessable
csbr10-q7312016.htm	Edgar Link	pending
csbr10-qex311.htm	Edgar Link	pending
csbr10-qex312.htm	Edgar Link	pending
csbr10-qex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2016 Q3 Form 10-Q Financial Statement

#000162828016019568 Filed on September 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2016 Q3 Form 10-Q Financial Statement

#000162828016019568 Filed on September 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr